Repair of large bone defects with the use of autologous bone marrow stromal cells.

By R. Quarto, M. Mastrogiacomo, R. Cancedda, S. Kutepov, V. Mukhachev, A. Lavroukov, E. Kon, M. Marcacci. New England Journal of Medicine, 2001

1,425 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Genetics, Urology

View Paper: https://www.semanticscholar.org/paper/8a972db4c7b6d2364e42e8751a7e3ebb10fdcd72

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. Rui Luís Reis
2. A. Salgado
3. H. Rashid
4. Z. Sheikh
5. V. Verma
6. Zohaib Khurshid
7. P. Bianco
8. M. Glogauer

In Genetics

1. P. Robey
2. P. Bianco
3. Frank Barry
4. Andrea Augello
5. C. De Bari
6. S. Gronthos
7. S. Shi

In Urology

1. Rui Luís Reis
2. Frank Barry
3. A. Salgado
4. O. Coutinho

Citations in the corpus

• Stem Cells Associated with Macroporous Bioceramics for Long Bone Repair: 6- to 7-Year Outcome of a Pilot Clinical Study (2007, neutral): “34 The aim of the present work was to determine the durability of this type of implant in this first group of patients treated with this innovative tissue engineering method.”
• Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. (2005, background): “Due to their accessibility, expandability, and multipotentiality, MSC hold promise for clinical applications [27–37].”
• The Regulation of Differentiation in Mesenchymal Stem Cells (2010, positive): “Using HA-based bioscaffolds, it then became possible to repair segmental bone defects in vivo by using autologous MSCs, under loaded conditions, both in large animals (Kon et al. , 2000) as well as in humans in proof-of-concept studies (Quarto et al. , 2001).”
• A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow (2009, background): “Effectiveness of MSCs in hematopoietic recovery, bone regeneration and in the treatment of patients with osteogenesis imperfecta, infracted myocardium or joint diseases has been well documente”
• Bone tissue engineering: state of the art and future trends. (2004, methodology): “Several reports [34,55-64] have shown that by using ceramics with, or without, bone marrow cells, good results regarding bone regeneration could be obtained.”
• Mesenchymal stem cells: clinical applications and biological characterization. (2004, background): “, 2003), the repair of segmental bone defects (Quarto et al., 2001) and craniotomy defects (Krebsbach, Mankani, Satomura, Kuznetsov, & Robey, 1998).”
• Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell‐based therapy applications (2005, background): “…applications in hematology disorders or bone defects caused by trauma or tumor removal depend upon their ex vivo expansion from a limited volume of BM to obtain at least some millions of undifferentiated cells prior to re-infusion (Bruder et al., 1998; Horwitz et al., 1999; Quarto et al., 2001).”
• Biodegradable Materials for Bone Repair and Tissue Engineering Applications (2015, methodology): “HA based bioceramics are used for small bone defect filling after tumor resection and/or after bone loss due to fractures in humerus, tibia, calceneus, radius and vertebra [101].”
• Stem cells in tissue engineering (2001, result): “Convincing preclinical studies adopting this approach have led to preliminary observational studies in human”